{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T21:05:21Z","timestamp":1771362321785,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jacadv.2025.102276","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T12:00:18Z","timestamp":1761652818000},"page":"102276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["FGF-23, hsCRP, Cardiovascular Events, and the Benefit of Canagliflozin in the CANVAS Trial"],"prefix":"10.1016","volume":"4","author":[{"given":"Aranya","family":"Punithan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehsan","family":"Ghamarian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Grothe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Macy","family":"MacLean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Connelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0490-7465","authenticated-orcid":false,"given":"Bruce","family":"Neal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alanna","family":"Weisman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Z.I.","family":"Cherney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2824-1215","authenticated-orcid":false,"given":"Filio","family":"Billia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob A.","family":"Udell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jacadv.2025.102276_bib1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/MED.0000000000000294","article-title":"FGF-23 and cardiovascular disease: review of literature","volume":"23","author":"Batra","year":"2016","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.jacadv.2025.102276_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.632260","article-title":"An overview of FGF-23 as a novel candidate biomarker of cardiovascular risk","volume":"12","author":"V\u00e1zquez-S\u00e1nchez","year":"2021","journal-title":"Front Physiol"},{"issue":"3","key":"10.1016\/j.jacadv.2025.102276_bib3","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/01.CIR.0000053730.47739.3C","article-title":"Clinical application of C-reactive protein for cardiovascular disease detection and prevention","volume":"107","author":"Ridker","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.102276_bib4","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3389\/fimmu.2018.00754","article-title":"Role of C-reactive protein at sites of inflammation and infection","volume":"9","author":"Sproston","year":"2018","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.jacadv.2025.102276_bib5","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/dmrr.2787","article-title":"Circulating fibroblast growth factor-23 plasma levels predict adverse cardiovascular outcomes in patients with diabetes mellitus with coronary artery disease","volume":"32","author":"Tu\u00f1\u00f3n","year":"2016","journal-title":"Diabetes Metabo Res Rev"},{"issue":"7","key":"10.1016\/j.jacadv.2025.102276_bib6","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jacadv.2025.102276_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2024.12.012","article-title":"Interleukin-6 in heart failure with reduced ejection fraction and the effect of dapagliflozin","volume":"13","author":"Docherty","year":"2025","journal-title":"JACC Heart Fail"},{"issue":"23","key":"10.1016\/j.jacadv.2025.102276_bib8","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021661","article-title":"Association between circulating GDF-15 and cardio-renal outcomes and effect of canagliflozin: results from the CANVAS trial","volume":"10","author":"Sen","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"10.1016\/j.jacadv.2025.102276_bib9","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s00125-021-05512-5","article-title":"Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial","volume":"64","author":"Sen","year":"2021","journal-title":"Diabetologia"},{"issue":"18","key":"10.1016\/j.jacadv.2025.102276_bib10","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.jacc.2020.09.004","article-title":"Effects of canagliflozin on amino-terminal pro\u2013B-type natriuretic peptide","volume":"76","author":"Januzzi","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.jacadv.2025.102276_bib11","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1161\/CIRCULATIONAHA.123.065251","article-title":"Cardiorenal biomarkers, canagliflozin, and outcomes in diabetic kidney disease: the CREDENCE trial","volume":"148","author":"Januzzi","year":"2023","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jacadv.2025.102276_bib12","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jacc.2017.06.016","article-title":"Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes","volume":"70","author":"Januzzi","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacadv.2025.102276_bib13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13098-018-0395-5","article-title":"Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance","volume":"10","author":"Hattori","year":"2018","journal-title":"Diabetol Metab Syndr"},{"issue":"21","key":"10.1016\/j.jacadv.2025.102276_bib14","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2007.02.052","article-title":"C-reactive protein and the prediction of cardiovascular events among those at intermediate risk. Moving an inflammatory hypothesis toward consensus","volume":"49","author":"Ridker","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jacadv.2025.102276_bib15","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/jamacardio.2018.0653","article-title":"Association of fibroblast growth factor 23 with recurrent cardiovascular events in patients after an acute coronary syndrome A secondary analysis of a randomized clinical trial","volume":"3","author":"Bergmark","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"3","key":"10.1016\/j.jacadv.2025.102276_bib16","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1161\/ATVBAHA.108.181735","article-title":"Prognostic utility of apoB\/AI, total cholesterol\/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22","volume":"29","author":"Ray","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.jacadv.2025.102276_bib17","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1161\/CIRCOUTCOMES.110.938118","volume":"3","author":"Ridker","year":"2010","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"8","key":"10.1016\/j.jacadv.2025.102276_bib18","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/01.CIR.98.8.731","article-title":"Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women","volume":"98","author":"Ridker","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.102276_bib19","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3389\/fendo.2018.00278","article-title":"Paracrine effects of FGF23 on the heart","volume":"9","author":"Leifheit-Nestler","year":"2018","journal-title":"Front Endocrinol"},{"issue":"4","key":"10.1016\/j.jacadv.2025.102276_bib20","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/ejhf.1424","article-title":"Klotho, fibroblast growth factor-23, and the renin\u2013angiotensin system \u2014 an analysis from the PEACE trial","volume":"21","author":"Bergmark","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"10.1016\/j.jacadv.2025.102276_bib21","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jacadv.2025.102276_bib22","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1038\/s41591-024-03043-1","article-title":"IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial","volume":"30","author":"Chertow","year":"2024","journal-title":"Nat Med"},{"issue":"26","key":"10.1016\/j.jacadv.2025.102276_bib23","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25007057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25007057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T20:05:36Z","timestamp":1771358736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X25007057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2772963X25007057"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.102276","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FGF-23, hsCRP, Cardiovascular Events, and the Benefit of Canagliflozin in the CANVAS Trial","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.102276","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102276"}}